Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis.
OBJECTIVE
To compare the early and late outcomes of primary percutaneous transluminal coronary angioplasty (PTCA) with fibrinolytic treatment among diabetic patients with acute myocardial infarction (AMI).


METHODS
Retrospective observational study with data obtained from prospective registries.


METHODS
Tertiary cardiovascular institution with 24 hour acute interventional facilities.


METHODS
202 consecutive diabetic patients with AMI receiving reperfusion treatment within six hours of symptom onset.


METHODS
Fibrinolytic treatment was administered to 99 patients, and 103 patients underwent primary PTCA. Most patients undergoing PTCA received adjunctive stenting (94.2%) and glycoprotein IIb/IIIa inhibition (63.1%).


METHODS
Death, non-fatal reinfarction, and target vessel revascularisation at 30 days and one year were assessed.


RESULTS
Baseline characteristics were similar in these two treatment groups except that the proportion of patients with Killip class III or IV was considerably higher in those treated with PTCA (15.5% v 6.1%, p = 0.03) and time to treatment was significantly longer (103.7 v 68.0 minutes, p < 0.001). Among those treated with PTCA, the rates for in-hospital recurrent ischaemia (5.8% v 17.2%, p = 0.011) and target vessel revascularisation at one year (19.4% v 36.4%, p = 0.007) were lower. Death or reinfarction at one year was also reduced among those treated with PTCA (17.5% v 31.3%, p = 0.02), with an adjusted relative risk of 0.29 (95% confidence interval 0.15 to 0.57) compared with fibrinolysis.


CONCLUSIONS
Among diabetic patients with AMI, primary PTCA was associated with reduced early and late adverse events compared with fibrinolytic treatment.
Hsu
L F
LF
Department of Cardiology, National Heart Centre, Singapore.
Mak
K H
KH
Lau
K W
KW
Sim
L L
LL
Chan
C
C
Koh
T H
TH
Chuah
S C
SC
Kam
R
R
Ding
Z P
ZP
Teo
W S
WS
Lim
Y L
YL
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000925:Anticoagulants / Q000008:administration & dosage; D003925:Diabetic Angiopathies / Q000628:therapy*; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006760:Hospitalization; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000628:therapy*; D012008:Recurrence; D012189:Retrospective Studies; D015607:Stents; D013300:Streptokinase / Q000008:administration & dosage; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D000077284:Abciximab